NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox
NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.
How this was made
The 30-second read
Why it matters
The filing adds concrete development and regulatory milestones (Phase II enrollment start dates, DRC approval, trial-site readiness) while also updating financial constraints (cash balance and runway to Nov 16, 2027). This combination can drive sentiment but also increases financing/dilution risk awareness.
Market read
Traders get a near-term catalyst mix: new Phase II trial starts and regulatory approval for NV-387, alongside a disclosed funding runway that can affect financing expectations.
What to watch
The article emphasizes setup and dosing/tolerability rationale but provides no Phase II efficacy outcomes yet; traders may need to discount the news until enrollment milestones and early safety/response readouts.
Background
NanoViricides (NNVC) reports filing its Form 10-Q for the quarter ended Sep 30, 2026 and updates NV-387 development, including two separate Phase II trials for Ebola BDBV and Mpox, plus Measles orphan designations.
Ticker impact
NanoViricides filed its 10-Q and disclosed NV-387 entering two Phase II trials, plus DRC regulatory approval and Ebola/Mpox trial setup progress.
Likely upward bias as trial initiation and regulatory approval reduce development uncertainty, partially offset by funding/runway concerns.
The article is a primary company filing plus specific trial-start and regulatory-approval updates, which are typically supportive for biotech sentiment. However, it also states insufficient funding to continue operations through Nov 16, 2027, which can cap upside and increase dilution/financing risk.
Market effects
Highlights ongoing demand for oral broad-spectrum antivirals and the market sensitivity to trial starts and cash runway in small-cap biotech.
No direct regional market catalyst beyond DRC trial operations and regulatory activity.
Ebola and Mpox trial focus ties to global public-health priorities, but the tradable impact is primarily company-specific.
Counterpoint
Trial initiation and regulatory approvals may not translate into near-term value without interim efficacy data, and the stated funding gap raises dilution risk that can overwhelm clinical optimism.
Key entities
- companyNanoViricides, Inc.
Issuer filing the quarterly report and advancing NV-387 into Phase II trials.
- drug_candidateNV-387
Broad-spectrum antiviral oral gummies entering Phase II trials for Ebola BDBV and Mpox, with Measles orphan designations.
- regulatorACOREP (DRC regulatory agency)
Granted approval to conduct the Ebola BDBV clinical trial in early August 2026.
- filingSEC Form 10-Q
Quarterly report filed Nov 16, 2026 for the quarter ended Sep 30, 2026.

